

Claim 5, line 1, delete "any one of claims 1-4" and insert --claim 1--.
Claim 6, line 1, delete "any one of claims 1-5" and insert --claim 1--.
Claim 7, line 1, delete "anyone of claims 1-6" and insert --claim 1--.
Claim 8, line 1, delete "anyone of claims 1-7" and insert --claim 1--.
Claim 9, line 1, delete "anyone of claims 1-8" and insert --claim 1--.
Claim 10, line 1, delete "anyone of claims 1-9" and insert --claim 1--.
Claim 11, line 1, delete "anyone of claims 1-10" and insert --claim 1--.

REMARKS

Claims 1-15 are pending in the present application. The claims have been amended to remove multiple dependencies. No new matter is introduced by this amendment.

Applicants enclose herewith the Sequence Listing for the above-captioned application and a 3.5" floppy disk containing the Sequence Listing. The content of the attached paper entitled "SEQUENCE LISTING" and of the accompanying identically labeled diskette is the same. Furthermore, the information contained in the attached "SEQUENCE LISTING" and the ASCII-encoded file is identical to the information in the specification. No new matter is added.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR § 1.821(c) and (e), respectively, are the same.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: January 25, 2001

Valeta A. Gregg
Valeta A. Gregg, Reg. No. 35,127
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 887-9638